Valneva Reports EMA Acceptance of VLA1553 for Chikungunya
Shots:
- The EMA has formally validated the MAA for VLA1553, confirming inclusion of essential regulatory elements followed by the accelerated assessment granted by the CHMP last month
- In early Dec, VLA1553 received approval from the US FDA under the brand name IXCHIQ for the prevention of disease caused by the chikungunya virus (CHIKV) in 18yrs. and older patients who are at greater risk to CHIKV
- Additionally, in mid-Nov, Valneva revealed P-III immunogenicity results for VLA1553 in adolescents, supporting a potential label extension. The trial aims to facilitate vaccine licensure in Brazil, marking a potential first approval for use in endemic populations
Ref: Valneva | Image: Valneva
Related News:- Valneva Reports Completion of VLA1553 in P-III (VLA1553-301) Trial for the Treatment of Chikungunya
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
